|
|
Latest Breast Cancer News
Lapatinib Approved for Initial Treatment of Metastatic Breast Cancer (2/2/2010)
The U.S. Food and Drug Administration (FDA) has expanded its approval of Tykerb® (lapatinib) to include initial treatment of metastatic, postmenopausal breast cancer that is both HER2-positive and hormone receptor-positive. In this setting, Tykerb is approved for use in combination with the aromatase inhibitor drug Femara® (letrozole).
Soy Foods May Benefit Breast Cancer Patients (1/29/2010)
According to a study conducted in China, breast cancer patients with the highest soy consumption had a lower risk of breast cancer recurrence and a lower risk of death than patients with the lowest soy consumption. An editorial that accompanied the study, however, offered some words of caution about these findings. The study and editorial were published in the Journal of the American Medical Association.
Exercise and Green Tea May Help Breast Cancer Survivors Beat the Blues (1/28/2010)
Exercising and drinking green tea may help prevent depression among breast cancer survivors, according to the results of a study published in the Journal of Clinical Oncology.
Oncotype DX® Influences Breast Cancer Treatment Decisions (1/12/2010)
Among women with early breast cancer, use of the OncotypeDX® test changed oncologist treatment recommendations in approximately 32% of cases. Use of the test also increased oncologist confidence in the treatment recommendation and decreased patient anxiety. These results were published in the Journal of Clinical Oncology.
Acupuncture Reduces Hot Flashes in Breast Cancer Patients (1/4/2010)
Among women treated with hormonal therapy for breast cancer, acupuncture and Effexor® (venlafaxine) were similarly effective at reducing the frequency of hot flashes. These results were published in the Journal of Clinical Oncology.
Breast Cancer News By Topic
Breast Cancer - Screening/PreventionSoy Foods May Benefit Breast Cancer Patients (1/29/2010)
According to a study conducted in China, breast cancer patients with the highest soy consumption had a lower risk of breast cancer recurrence and a lower risk of death than patients with the lowest soy consumption. An editorial that accompanied the study, however, offered some words of caution about these findings. The study and editorial were published in the Journal of the American Medical Association.
Many Women at Increased Risk of Breast Cancer Refuse MRIs (12/29/2009)
In a breast cancer screening study, 42% of intermediate- and high-risk women who were offered breast magnetic resonance imaging (MRI) refused the procedure. The most common reason given for refusal was claustrophobia. These results were published in Radiology.
MRI Screening May Detect Breast Cancer Earlier Among BRCA Carriers (12/11/2009)
The addition of MRI to mammography screening in women with a BRCA mutation appears to significantly reduce the incidence of advanced breast cancer, according to the results of a study presented at the 2009 San Antonio Breast Cancer Symposium.
Bisphosphonates May Provide Breast Cancer Benefits (12/11/2009)
Studies presented at the 2009 San Antonio Breast Cancer Symposium suggest that the class of bone drugs known as bisphosphonates may reduce the risk of breast cancer and may help to maintain bone density in breast cancer patients treated with aromatase inhibitors.
Mammography May Increase Breast Cancer Risk in Some High-risk Women (12/2/2009)
According to a combined analysis of previous studies, low-dose radiation from annual mammograms may increase the risk of breast cancer among women with genetic or familial predisposition to the disease. These results were presented at the annual meeting of the Radiological Society of North America.
Breast Cancer - Carcinoma In SituAcupuncture Reduces Hot Flashes in Breast Cancer Patients (1/4/2010)
Among women treated with hormonal therapy for breast cancer, acupuncture and Effexor® (venlafaxine) were similarly effective at reducing the frequency of hot flashes. These results were published in the Journal of Clinical Oncology.
Young Women with DCIS Have Higher Risk of Recurrence (10/12/2009)
After treatment of breast ductal carcinoma in situ (DCIS) with breast-conserving surgery and radiation therapy, women age 44 or younger have a higher rate of recurrence than older women. These results were presented at the ASCO 2009 Breast Cancer Symposium.
Surgical Decision-making in Early-stage Breast Cancer (9/15/2009)
Patients with early-stage breast cancer who take an active role in decision-making tend to opt for mastectomy over lumpectomy, despite the fact that the procedures have been shown to produce equivalent outcomes, according to the results of a study published in the Journal of the National Cancer Institute.
Mammography Screening Important After Lumpectomy for DCIS (7/16/2009)
Surveillance mammography after breast-conserving surgery for ductal carcinoma in situ (DCIS) appears to decline over time, despite the increased risk of invasive cancer, according to the results of a study published in the Journal of Clinical Oncology.
HER2 Overexpression Predicts Invasive Breast Cancer in Women with DCIS (6/1/2009)
According to the results of a study published in Cancer Epidemiology, Biomarkers & Prevention, women with ductal carcinoma in situ (DCIS) that has high levels of the HER2 protein are several times more likely than other women with DCIS to have invasive breast cancer.
Breast Cancer - Stage I Node NegativeOncotype DX® Influences Breast Cancer Treatment Decisions (1/12/2010)
Among women with early breast cancer, use of the OncotypeDX® test changed oncologist treatment recommendations in approximately 32% of cases. Use of the test also increased oncologist confidence in the treatment recommendation and decreased patient anxiety. These results were published in the Journal of Clinical Oncology.
Acupuncture Reduces Hot Flashes in Breast Cancer Patients (1/4/2010)
Among women treated with hormonal therapy for breast cancer, acupuncture and Effexor® (venlafaxine) were similarly effective at reducing the frequency of hot flashes. These results were published in the Journal of Clinical Oncology.
Herceptin® Given Concurrently with Chemotherapy May Provide Most Benefit (12/16/2009)
The results of a Phase III clinical trial confirm that Herceptin® (trastuzumab) reduces the risk of recurrence among women with early-stage, HER2-positive breast cancer, and also suggest that treatment with Herceptin should begin concurrently with chemotherapy. These results were presented at the 2009 San Antonio Breast Cancer Symposium.
Combination of Herceptin® with Non–anthracycline-based Chemotherapy Appears to Be Effective (12/15/2009)
Among women with early, HER2-positive breast cancer, the addition of Herceptin® (trastuzumab) to adjuvant chemotherapy reduces the risk of cancer recurrence and improves survival. Herceptin provides a benefit in combination with either anthracycline- or non–anthracycline-based chemotherapy regimens. These results were presented at the 2009 San Antonio Breast Cancer Symposium.
Black Women with HR-positive Breast Cancer Have Worse Outcomes (12/14/2009)
Black women with hormone receptor (HR)-positive breast cancer have worse disease-free and overall survival than women of other races, according to the results of a study presented at the 2009 San Antonio Breast Cancer Symposium.
Breast Cancer - Stages II-IIIOncotype DX® Influences Breast Cancer Treatment Decisions (1/12/2010)
Among women with early breast cancer, use of the OncotypeDX® test changed oncologist treatment recommendations in approximately 32% of cases. Use of the test also increased oncologist confidence in the treatment recommendation and decreased patient anxiety. These results were published in the Journal of Clinical Oncology.
Acupuncture Reduces Hot Flashes in Breast Cancer Patients (1/4/2010)
Among women treated with hormonal therapy for breast cancer, acupuncture and Effexor® (venlafaxine) were similarly effective at reducing the frequency of hot flashes. These results were published in the Journal of Clinical Oncology.
Herceptin® Given Concurrently with Chemotherapy May Provide Most Benefit (12/16/2009)
The results of a Phase III clinical trial confirm that Herceptin® (trastuzumab) reduces the risk of recurrence among women with early-stage, HER2-positive breast cancer, and also suggest that treatment with Herceptin should begin concurrently with chemotherapy. These results were presented at the 2009 San Antonio Breast Cancer Symposium.
Combination of Herceptin® with Non–anthracycline-based Chemotherapy Appears to Be Effective (12/15/2009)
Among women with early, HER2-positive breast cancer, the addition of Herceptin® (trastuzumab) to adjuvant chemotherapy reduces the risk of cancer recurrence and improves survival. Herceptin provides a benefit in combination with either anthracycline- or non–anthracycline-based chemotherapy regimens. These results were presented at the 2009 San Antonio Breast Cancer Symposium.
Oncotype DX® Influences Treatment Decisions in Node-positive Breast Cancer (12/14/2009)
Use of the Oncotype DX® test to estimate recurrence risk and chemotherapy benefit influences treatment decisions for women with node-positive breast cancer. These results were presented at the San Antonio Breast Cancer Symposium (SABCS).
Breast Cancer - InflammatoryTykerb® Shows Benefit in Inflammatory Breast Cancer (5/14/2009)
In a Phase II clinical trial, treatment with the targeted therapy Tykerb® (lapatinib) reduced the extent of cancer in 39% of women with HER2-positive, relapsed or refractory inflammatory breast cancer. These results were published in Lancet Oncology.
FDA Approves New Test to Detect HER2 Status in Breast Cancer (7/10/2008)
The U.S. Food and Drug Administration (FDA) has approved a new laboratory test to help identify patients with breast cancer who may benefit from treatment with Herceptin® (trastuzumab).
Tykerb® Effective in Recurrent Inflammatory Breast Cancer (6/6/2008)
Among women with recurrent HER2-positive inflammatory breast cancer (IBC), treatment with Tykerb® (lapatinib) is effective, even among patients whose cancer has progressed following treatment with Herceptin® (trastuzumab). These results were recently reported at the 2008 annual meeting of the American Society of Clinical Oncology.
Specific Gene Mutations May Affect Response to Tamoxifen in Breast Cancer (5/6/2008)
Mutations within the CYP2D6 gene may affect the way in which a patient with hormone-positive breast cancer responds to tamoxifen (Nolvadex®). These results were recently published in the Journal of the National Cancer Institute.
Large Majority of Breast Cancer Information on Internet Is Accurate (2/11/2008)
Approximately 95% of information about breast cancer that is found on the Internet is accurate. These results were recently published in the journal Cancer.
Breast Cancer - MetastaticLapatinib Approved for Initial Treatment of Metastatic Breast Cancer (2/2/2010)
The U.S. Food and Drug Administration (FDA) has expanded its approval of Tykerb® (lapatinib) to include initial treatment of metastatic, postmenopausal breast cancer that is both HER2-positive and hormone receptor-positive. In this setting, Tykerb is approved for use in combination with the aromatase inhibitor drug Femara® (letrozole).
Neratinib Shows Promise in Treatment of HER2-positive Breast Cancer (12/16/2009)
According to the results of a Phase II clinical trial, the addition of the investigational drug neratinib to paclitaxel chemotherapy produced promising response rates among women with metastatic, HER2-positive breast cancer. These results were presented at the 2009 San Antonio Breast Cancer Symposium.
Combination of Tykerb® and Herceptin® Benefits Breast Cancer Patients Who Have Progressed on Herceptin (12/15/2009)
Among women with HER2-positive, metastatic breast cancer that has progressed during treatment with Herceptin® (trastuzumab), the combination of Tykerb® (lapatinib) and Herceptin appears to be more effective than Tykerb alone. These results were presented at the 2009 San Antonio Breast Cancer Symposium.
Addition of Avastin® to Chemotherapy Delays Breast Cancer Progression (12/15/2009)
According to the results of two Phase III clinical trials, the addition of Avastin® (bevacizumab) to first- or second-line chemotherapy delays cancer progression but may not improve overall survival among women with advanced breast cancer. These results were presented at the 2009 San Antonio Breast Cancer Symposium (SABCS).
Nexavar® Evaluated in Locally Recurrent or Metastatic Breast Cancer (12/14/2009)
According to the results of a Phase II clinical trial, the addition of the targeted therapy Nexavar® (sorafenib) to chemotherapy may delay cancer progression among women with locally recurrent or metastatic, HER2-negative breast cancer. These results were presented at the 2009 San Antonio Breast Cancer Symposium.
Breast Cancer - RecurrentNeratinib Shows Promise in Treatment of HER2-positive Breast Cancer (12/16/2009)
According to the results of a Phase II clinical trial, the addition of the investigational drug neratinib to paclitaxel chemotherapy produced promising response rates among women with metastatic, HER2-positive breast cancer. These results were presented at the 2009 San Antonio Breast Cancer Symposium.
Combination of Tykerb® and Herceptin® Benefits Breast Cancer Patients Who Have Progressed on Herceptin (12/15/2009)
Among women with HER2-positive, metastatic breast cancer that has progressed during treatment with Herceptin® (trastuzumab), the combination of Tykerb® (lapatinib) and Herceptin appears to be more effective than Tykerb alone. These results were presented at the 2009 San Antonio Breast Cancer Symposium.
Addition of Avastin® to Chemotherapy Delays Breast Cancer Progression (12/15/2009)
According to the results of two Phase III clinical trials, the addition of Avastin® (bevacizumab) to first- or second-line chemotherapy delays cancer progression but may not improve overall survival among women with advanced breast cancer. These results were presented at the 2009 San Antonio Breast Cancer Symposium (SABCS).
Nexavar® Evaluated in Locally Recurrent or Metastatic Breast Cancer (12/14/2009)
According to the results of a Phase II clinical trial, the addition of the targeted therapy Nexavar® (sorafenib) to chemotherapy may delay cancer progression among women with locally recurrent or metastatic, HER2-negative breast cancer. These results were presented at the 2009 San Antonio Breast Cancer Symposium.
Nexavar Shows Promise in Advanced Breast Cancer (9/30/2009)
According to the results of a Phase II clinical trial, the addition of the targeted therapy Nexavar® (sorafenib) to chemotherapy may delay the progression of advanced breast cancer. These results were presented at a European cancer conference.
Breast Cancer - Supportive CareExercise and Green Tea May Help Breast Cancer Survivors Beat the Blues (1/28/2010)
Exercising and drinking green tea may help prevent depression among breast cancer survivors, according to the results of a study published in the Journal of Clinical Oncology.
Acupuncture Reduces Hot Flashes in Breast Cancer Patients (1/4/2010)
Among women treated with hormonal therapy for breast cancer, acupuncture and Effexor® (venlafaxine) were similarly effective at reducing the frequency of hot flashes. These results were published in the Journal of Clinical Oncology.
Home Care Nursing Improves Symptom Management (12/4/2009)
Among breast and colorectal cancer patients treated with the oral chemotherapy drug Xeloda® (capecitabine), symptom management was better among patients who received home care nursing than among patients who received standard care. These results were published in the Journal of Clinical Oncology.
Breast Cancer Patients Use Antioxidant Supplements During Treatment (7/15/2009)
Although the consequences of supplementing with antioxidants during cancer treatment remain unknown, many patients with breast cancer continue to use the supplements in an effort to maintain health and diminish the side effects of treatment, according to the results of a study published in Cancer.
Advances in Breast Cancer Treatment 2008 (3/10/2009)
Twenty to 25 percent of breast cancers overexpress (make too much of) a protein known as HER2. Overexpression of this protein leads to increased growth of cancer cells and a worse breast cancer prognosis.
|
|
